首页> 外文期刊>European journal of drug metabolism and pharmacokinetics >The interaction of the diltiazem with oral and intravenous cyclosporine in rats.
【24h】

The interaction of the diltiazem with oral and intravenous cyclosporine in rats.

机译:地尔硫卓与大鼠口服和静脉内环孢霉素的相互作用。

获取原文
获取原文并翻译 | 示例
       

摘要

This study investigated the effect of diltiazem on the bioavailability of oral and intravenous cyclosporine (CsA) in rats. While control rats received normal saline, experimental groups received 60 or 90 mg/kg diltiazem orally for 3 days. Each group divided into 2 equal groups that received a single oral dose or i.v. injection of CsA. Pharmacokinetic parameters were analyzed by nonparametric analysis of variance. Pretreatment with 60 or 90 mg/kg diltiazem decreased the area under the blood CsA concentration-time curve (AUC) of oral CsA compared to control group (54.5% and 65.5% for AUC(0-24), 57.6% and 62.2% for AUC(0-infinity), respectively, p<0.05). Mean CsA maximum concentration (Cmax) decreased from 0.4 +/- 0.1 microg/ml to 0.1 +/- 0.0 microg/mL in rats pretreated with 90 mg/kg diltiazem (p<0.05). The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%). Pretreatment with 90 mg/kg but not 60 mg/kg of diltiazem increased the AUC(0-infinity), elimination half-life (t1/2) of intravenous CsA (116.0%, 219.2%, respectively, p<0.05) and decreased the intravenous CsA clearence (CL(i.v.)) (62.9%, p<0.05). Diltiazem decreased the bioavailability of oral CsA, while it increased the bioavailability of intravenous CsA. One must consider this interaction when administering oral or intravenous CsA concomitantly with diltiazem.
机译:这项研究调查了地尔硫卓对大鼠口服和静脉内环孢素(CsA)生物利用度的影响。对照组大鼠接受生理盐水,实验组口服60或90 mg / kg地尔硫卓3天。每一组分为2个相等的组,分别接受一次口服或静脉注射。注射CsA。通过方差的非参数分析来分析药代动力学参数。用60或90 mg / kg地尔硫卓预处理可降低口服CsA的血液CsA浓度-时间曲线(AUC)下面积,与对照组相比(AUC(0-24)为54.5%和65.5%,AUC(0-24)为57.6%和62.2% AUC(0-无穷大)分别为p <0.05)。在用90 mg / kg地尔硫卓预处理的大鼠中,平均CsA最大浓度(Cmax)从0.4 +/- 0.1微克/毫升降低到0.1 +/- 0.0微克/毫升(p <0.05)。 60或90 mg / kg地尔硫卓组口服后的绝对生物利用度(F(p.o。))低于对照组(9.6%和8.5%对22.6%)。用地尔硫卓90 mg / kg而非60 mg / kg进行预处理可增加静脉CsA的AUC(0-无穷大),消除半衰期(t1 / 2)(分别为116.0%,219.2%,p <0.05)并降低静脉CsA清除率(CL(iv))(62.9%,p <0.05)。地尔硫卓降低口服CsA的生物利用度,而增加静脉内CsA的生物利用度。在与地尔硫卓同时口服或静脉注射CsA时,必须考虑这种相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号